Evidence map›Paper›PMID 41647356›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Synthesis, radiolabeling, and evaluation of a

Jiajun Xie, Weiguo Xu, Hui Deng, Xiaoai Wu, Jing Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jiajun Xie *NHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL), Mianyang, China.
Weiguo Xu *Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Hui DengPrecision Medicine Key Laboratory of Sichuan Province, West China Hospital of Sichuan University, Chengdu, China.
Xiaoai WuDepartment of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
Jing ZhuNHC Key Laboratory of Nuclear Technology Medical Transformation (MIANYANG CENTRAL HOSPITAL), Mianyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiolabeled tyrosine kinase inhibitors (TKIs) have been used in clinics for the detection of epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) patients by positron emission tomography (PET), and the potential responder for TKI targeted therapy can be selected and benefited in subsequent TKI-based anti-tumor treatment. However, as activated T790M resistance mutation is often observed in NSCLC patients underwent EGFR TKI based therapies, the detection of EGFR mutation status is of great importance to evaluate therapeutic efficacy and prolongs overall survival with these patients. In addition, no radiotracer has been reported with the ability to detect EGFR

Indexed as

EGFRlung cancerPETradiotracerT790M

Identifiers

PMID41647356
PMCPMC12868298

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.